Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 13 | 2025 | 278 | 3.420 |
Why?
|
| Socioeconomic Factors | 11 | 2025 | 872 | 1.970 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 930 | 1.820 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1314 | 1.630 |
Why?
|
| Texas | 22 | 2024 | 3588 | 1.300 |
Why?
|
| Cyclonic Storms | 4 | 2023 | 75 | 1.230 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 237 | 1.070 |
Why?
|
| Transportation | 2 | 2019 | 26 | 1.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 783 | 0.980 |
Why?
|
| Walking | 4 | 2019 | 215 | 0.840 |
Why?
|
| Schools | 5 | 2025 | 219 | 0.840 |
Why?
|
| Environment Design | 4 | 2019 | 15 | 0.830 |
Why?
|
| Registries | 7 | 2024 | 1435 | 0.830 |
Why?
|
| Health Status Disparities | 4 | 2024 | 228 | 0.820 |
Why?
|
| Floods | 3 | 2022 | 13 | 0.820 |
Why?
|
| Arsenic | 1 | 2023 | 46 | 0.800 |
Why?
|
| Social Class | 3 | 2025 | 190 | 0.730 |
Why?
|
| Pediatric Obesity | 5 | 2017 | 383 | 0.670 |
Why?
|
| Disasters | 1 | 2021 | 103 | 0.650 |
Why?
|
| Public Facilities | 1 | 2019 | 2 | 0.640 |
Why?
|
| Bicycling | 1 | 2019 | 35 | 0.620 |
Why?
|
| Hypersensitivity | 1 | 2021 | 185 | 0.610 |
Why?
|
| Incidence | 8 | 2024 | 3148 | 0.600 |
Why?
|
| Geographic Information Systems | 2 | 2015 | 41 | 0.580 |
Why?
|
| Overweight | 1 | 2020 | 364 | 0.570 |
Why?
|
| Stress, Psychological | 2 | 2021 | 560 | 0.560 |
Why?
|
| Pandemics | 5 | 2023 | 1111 | 0.530 |
Why?
|
| Mexican Americans | 2 | 2015 | 202 | 0.510 |
Why?
|
| Exercise | 2 | 2019 | 816 | 0.490 |
Why?
|
| Communicable Disease Control | 5 | 2023 | 138 | 0.450 |
Why?
|
| Safety | 2 | 2016 | 217 | 0.450 |
Why?
|
| Humans | 49 | 2025 | 125269 | 0.430 |
Why?
|
| Male | 39 | 2025 | 61560 | 0.420 |
Why?
|
| Female | 34 | 2025 | 66844 | 0.410 |
Why?
|
| Spatial Analysis | 2 | 2024 | 21 | 0.410 |
Why?
|
| Health Behavior | 4 | 2020 | 385 | 0.410 |
Why?
|
| Adult | 17 | 2024 | 29652 | 0.380 |
Why?
|
| Fenfluramine | 3 | 1997 | 11 | 0.370 |
Why?
|
| Motor Activity | 2 | 2014 | 520 | 0.360 |
Why?
|
| Parents | 2 | 2016 | 1026 | 0.350 |
Why?
|
| Environmental Exposure | 2 | 2024 | 220 | 0.340 |
Why?
|
| Middle Aged | 12 | 2024 | 26943 | 0.310 |
Why?
|
| Analgesics | 4 | 1994 | 127 | 0.310 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3432 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 537 | 0.290 |
Why?
|
| Child | 15 | 2025 | 24431 | 0.260 |
Why?
|
| Aged | 8 | 2024 | 19881 | 0.250 |
Why?
|
| Surveys and Questionnaires | 9 | 2022 | 3738 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2024 | 14029 | 0.250 |
Why?
|
| Research Design | 5 | 2020 | 695 | 0.240 |
Why?
|
| United States | 12 | 2023 | 10918 | 0.240 |
Why?
|
| Social Environment | 2 | 2016 | 120 | 0.240 |
Why?
|
| Sex Characteristics | 3 | 2023 | 314 | 0.240 |
Why?
|
| Adolescent | 12 | 2025 | 19362 | 0.230 |
Why?
|
| Young Adult | 7 | 2024 | 9056 | 0.230 |
Why?
|
| Culex | 1 | 2024 | 33 | 0.230 |
Why?
|
| Mosquito Vectors | 1 | 2024 | 35 | 0.230 |
Why?
|
| Geography, Medical | 1 | 2023 | 16 | 0.220 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 94 | 0.210 |
Why?
|
| Serotonin | 2 | 1994 | 219 | 0.210 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 139 | 0.200 |
Why?
|
| Hypothalamus | 2 | 1994 | 213 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 144 | 0.200 |
Why?
|
| Pain | 4 | 2022 | 451 | 0.200 |
Why?
|
| Endocrine Disruptors | 1 | 2022 | 51 | 0.190 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 117 | 0.190 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2022 | 67 | 0.180 |
Why?
|
| Arginine Vasopressin | 2 | 1992 | 28 | 0.180 |
Why?
|
| Sociological Factors | 1 | 2021 | 8 | 0.180 |
Why?
|
| Workplace Violence | 1 | 2020 | 3 | 0.180 |
Why?
|
| Social Isolation | 1 | 2020 | 42 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2023 | 443 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 296 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 78 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 482 | 0.170 |
Why?
|
| Public Opinion | 1 | 2020 | 56 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 178 | 0.160 |
Why?
|
| House Calls | 1 | 2020 | 39 | 0.160 |
Why?
|
| Receptors, Serotonin | 2 | 1997 | 42 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 167 | 0.160 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1826 | 0.160 |
Why?
|
| Stress, Physiological | 2 | 1991 | 254 | 0.160 |
Why?
|
| Cities | 1 | 2019 | 47 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 197 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 248 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 136 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 257 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2021 | 378 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 339 | 0.150 |
Why?
|
| Social Media | 1 | 2020 | 105 | 0.150 |
Why?
|
| Educational Status | 2 | 2021 | 276 | 0.150 |
Why?
|
| Health Status | 1 | 2020 | 377 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 607 | 0.150 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 119 | 0.150 |
Why?
|
| Mental Health | 1 | 2020 | 347 | 0.140 |
Why?
|
| Eating | 2 | 1997 | 368 | 0.140 |
Why?
|
| Community Networks | 1 | 2017 | 33 | 0.140 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1997 | 3 | 0.140 |
Why?
|
| Interleukin-1 | 2 | 1995 | 142 | 0.140 |
Why?
|
| Thiazepines | 1 | 1997 | 8 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 26 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 22 | 0.140 |
Why?
|
| Fluoxetine | 1 | 1997 | 43 | 0.130 |
Why?
|
| Behavior, Animal | 3 | 1997 | 490 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 447 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2023 | 855 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 398 | 0.130 |
Why?
|
| Attitude to Health | 2 | 2015 | 258 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1330 | 0.130 |
Why?
|
| Mice, Inbred Strains | 6 | 1995 | 308 | 0.130 |
Why?
|
| Neoplasms | 3 | 2024 | 2790 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 576 | 0.120 |
Why?
|
| Prednisolone | 1 | 1995 | 74 | 0.120 |
Why?
|
| Indomethacin | 1 | 1995 | 84 | 0.120 |
Why?
|
| Survival Rate | 1 | 2020 | 2062 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2023 | 16360 | 0.120 |
Why?
|
| Norfenfluramine | 1 | 1994 | 1 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.120 |
Why?
|
| Family Relations | 1 | 2015 | 68 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 434 | 0.110 |
Why?
|
| Naloxone | 2 | 1991 | 48 | 0.110 |
Why?
|
| School Health Services | 1 | 2015 | 99 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2014 | 90 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5180 | 0.110 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 69 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 588 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 172 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2015 | 218 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 307 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 1992 | 11 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 293 | 0.100 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 40 | 0.100 |
Why?
|
| Asthma | 1 | 2020 | 756 | 0.100 |
Why?
|
| Dopamine | 1 | 1994 | 283 | 0.100 |
Why?
|
| Codeine | 1 | 1992 | 22 | 0.100 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 10 | 0.100 |
Why?
|
| Morphine | 1 | 1992 | 83 | 0.100 |
Why?
|
| Students | 1 | 2014 | 249 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1992 | 128 | 0.090 |
Why?
|
| Histamine | 1 | 1991 | 45 | 0.090 |
Why?
|
| Models, Educational | 1 | 2011 | 74 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 8 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 776 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4646 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1327 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 48 | 0.090 |
Why?
|
| Research Personnel | 1 | 2011 | 117 | 0.090 |
Why?
|
| Analgesia | 1 | 1990 | 42 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 1994 | 780 | 0.080 |
Why?
|
| Nociceptors | 1 | 1990 | 15 | 0.080 |
Why?
|
| Injections, Intraventricular | 4 | 1992 | 63 | 0.080 |
Why?
|
| Animals | 12 | 2024 | 34238 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 1994 | 702 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1565 | 0.070 |
Why?
|
| Inflammation | 1 | 1995 | 1446 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1243 | 0.070 |
Why?
|
| Brain | 2 | 1997 | 3004 | 0.070 |
Why?
|
| Pain Measurement | 3 | 1994 | 345 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 684 | 0.070 |
Why?
|
| Sex Factors | 2 | 2021 | 1289 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2011 | 519 | 0.060 |
Why?
|
| Population Density | 1 | 2024 | 34 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.060 |
Why?
|
| Rats | 3 | 1997 | 3727 | 0.060 |
Why?
|
| Risk Factors | 3 | 2025 | 10319 | 0.060 |
Why?
|
| Mice | 8 | 1995 | 17635 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 30 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2825 | 0.050 |
Why?
|
| Environmental Health | 1 | 2023 | 14 | 0.050 |
Why?
|
| Firearms | 1 | 2024 | 42 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 110 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2024 | 139 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 200 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 164 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 115 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 75 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 37 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 79 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 73 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 33 | 0.050 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 179 | 0.050 |
Why?
|
| Marital Status | 1 | 2021 | 33 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 187 | 0.050 |
Why?
|
| Physical Exertion | 2 | 1991 | 78 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1812 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 140 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 357 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1991 | 137 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 23 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 70 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 299 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1697 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 199 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 113 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 362 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1360 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 964 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 517 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 175 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 12517 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 249 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 99 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 227 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2459 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 416 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 267 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 221 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 616 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 1997 | 14 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1251 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 1997 | 34 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 109 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 79 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 4 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 21 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 69 | 0.030 |
Why?
|
| Formaldehyde | 2 | 1992 | 36 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 77 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 68 | 0.030 |
Why?
|
| Fenclonine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 854 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1535 | 0.030 |
Why?
|
| Microdialysis | 1 | 1994 | 57 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 79 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 51 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 685 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1994 | 29 | 0.030 |
Why?
|
| Food Deprivation | 1 | 1994 | 32 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 135 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 1994 | 190 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 1994 | 162 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 127 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 381 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 989 | 0.020 |
Why?
|
| Oxymorphone | 1 | 1992 | 1 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 684 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1070 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 1991 | 3 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2914 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 1991 | 19 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 40 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2014 | 323 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 389 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 1992 | 109 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4818 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8236 | 0.020 |
Why?
|
| Parenting | 1 | 2015 | 332 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 138 | 0.020 |
Why?
|
| Swimming | 1 | 1990 | 22 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1990 | 177 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1939 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 216 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 257 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2714 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 728 | 0.020 |
Why?
|
| Reaction Time | 1 | 1990 | 175 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3892 | 0.020 |
Why?
|
| Anxiety | 1 | 2015 | 957 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 336 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2058 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 1899 | 0.020 |
Why?
|
| Diet | 1 | 1994 | 1140 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6603 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1991 | 59 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1991 | 125 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 136 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1991 | 494 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1375 | 0.000 |
Why?
|